Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model
Author:
- 2 January 2017
- journal article
- research article
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 9 (1) , 25-34
Abstract
For designing single-arm phase II trials with time-to-event endpoints, a sample size formula is derived for the modified one-sample log-rank test under the proportional hazards model. The derived formula enables new methods for designing trials that allow a flexible choice of the underlying survival distribution. Simulation results showed that the proposed formula provides an accurate estimation of sample size. The sample size calculation has been implemented in an R function for the purpose of trial design. Supplementary materials for this article are available online.Keywords
This publication has 17 references indexed in Scilit:
- Phase II clinical trials with time‐to‐event endpoints: optimal two‐stage designs with one‐sample log‐rank testStatistics in Medicine, 2013
- Estimating the loss in expectation of life due to cancer using flexible parametric survival modelsStatistics in Medicine, 2013
- Survival estimation through the cumulative hazard function with monotone natural cubic splinesLifetime Data Analysis, 2012
- Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-overStatistics in Medicine, 2006
- Comparing Survival of a Sample to That of a Standard PopulationJNCI: Journal of the National Cancer Institute, 2003
- A General Theory on Stochastic Curtailment for Censored Survival DataJournal of the American Statistical Association, 1999
- Logspline Density Estimation for Censored DataJournal of Computational and Graphical Statistics, 1992
- Introduction to sample size determination and power analysis for clinical trialsControlled Clinical Trials, 1981
- Analysis of Survival Data under the Proportional Hazards ModelInternational Statistical Review, 1975
- Planning the size and duration of a clinical trial studying the time to some critical eventJournal of Chronic Diseases, 1974